bazedoxifene: Clinical Trials

8 trials of bazedoxifene, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 unknown. 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 38Completed 7, Unknown 1

Follow bazedoxifene: new trials by email Literature Review of bazedoxifene trials Research Report on bazedoxifene

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea
Duavive (0.45 estrogens mg and 20 mg bazedoxifene) - Sleep Apnea, Post Menopausal
Phase 3UnknownLaval University362019-11-012022-04-08
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg - Menopause, Osteoporosis
Phase 3CompletedPfizer18862009-01-012014-04-08
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
Bazedoxifene/Conjugated Estrogen - Vasomotor Symptoms Associated With Menopause
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer3252005-10-012007-12-28
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
Bazedoxifene/Conjugated Estrogen - Vaginal Atrophy
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer6502005-10-012007-12-28
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo - Endometrial Hyperplasia, Osteoporosis
Phase 3CompletedPfizer10832005-09-012013-12-20
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Bazedoxifene/Conjugate Estrogens (CE), Raloxifene, Placebo - Endometrial Hyperplasia, Osteoporosis
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer35442002-04-012008-05-12
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
Bazedoxifene Acetate, Placebo - Osteoporosis
Phase 3CompletedPfizer76092001-12-012013-04-10
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
Bazedoxifene Acetate (TSE-424) - Osteoporosis
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer17422001-07-012009-08-21

Conditions studied

Osteoporosis (5)  ·  Endometrial Hyperplasia (2)  ·  Osteoporosis, Postmenopausal (1)  ·  Sleep Apnea Syndromes (1)

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer (4)  ·  Pfizer (3)  ·  Laval University (1)

Countries

United States (5)  ·  Argentina (2)  ·  Australia (2)  ·  Canada (2)  ·  Chile (2)  ·  Denmark (2)  ·  Finland (2)  ·  Hungary (2)  ·  Mexico (2)  ·  New Zealand (2)  ·  Norway (2)  ·  Poland (2)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)

Results publications

PMID 27676118, PMID 19635615, PMID 20569451, PMID 23635731, PMID 24438370, PMID 28539177, PMID 37619252